PDS Biotechnology Corporation (PDSB)

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its lead product candidate is PDS0101, a monotherapy first line therapy for cervical intraepithelial neoplasia of cancer. In addition, the company develops PDS0102, which is in phase 2 clinical trial for treatment of prostate and breast cancers. Further, its pipeline product portfolio includes PDS0103 for treatment of colorectal, breast, ovarian, and lung cancers; and PDS 0104 for treatment of melanoma. Additionally, the company offers Versamune, a T-cell activating platform developed for immunotherapy approaches, such as checkpoint inhibitors, CAR-T cells and live-vector based vaccines, etc. The company has collaboration agreement with Merck and Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer. PDS Biotechnology Corporation was incorporated in 2009 and is based in Berkeley Heights, New Jersey.

Current Quote*
Last: $3.050
Change: 0.190
Book: $0.704
Volume: 10,806

As Of: 10/22 13:02 ET
*Quotes delayed by 20min.

Graphs for PDSB

3 Month Graph

6 Month Graph

1 Year Graph